# Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

> **NCT03495960** · PHASE2 · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 72 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Methotrexate
- **DRUG:** Procarbazine
- **DRUG:** Lenalidomide
- **RADIATION:** Radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03495960
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-15
- **Primary completion:** 2024-12-12
- **Final completion:** 2024-12-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03495960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03495960, "Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03495960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*